Psychopharmacology :新研究表明绿茶可增强工作记忆

2014-04-17 佚名 网易科技

如果说绿茶是一位名人,那么它已经接近了头号大腕的宝座。其活性成分已经被证明对健康有多种益处,包括减轻体重、减少焦虑情绪以及抑制癌细胞的增长。现在一项新的研究表明,它的益处还包括“增强记忆”。 瑞士巴塞尔大学(University of Basel)的研究人员进行了一项简单的实验,在实验中,他们为受试者准备了两种饮料,其中一种饮料中含有27.5克绿茶提取物,还有一种是绿茶味的乳清蛋白饮料,研究人员随

如果说绿茶是一位名人,那么它已经接近了头号大腕的宝座。其活性成分已经被证明对健康有多种益处,包括减轻体重、减少焦虑情绪以及抑制癌细胞的增长。现在一项新的研究表明,它的益处还包括“增强记忆”。

瑞士巴塞尔大学(University of Basel)的研究人员进行了一项简单的实验,在实验中,他们为受试者准备了两种饮料,其中一种饮料中含有27.5克绿茶提取物,还有一种是绿茶味的乳清蛋白饮料,研究人员随机递给了受试者其中一种,没有告知他们所喝的是哪种饮料。

在他们饮用这两种饮料时,研究人员用功能性磁共振成像(fMRI)仪检查了他们的大脑。研究人员还要求受试者完成一些任务,从而测试他们的工作记忆(又名短期记忆)。

研究结果表明:那些喝绿茶提取物饮料的受试者在记忆任务中表现得更好,他们的大脑显示出了额叶和顶叶之间明显不同的激活模式。我们大部分最高级的思维能力都来源于额叶,顾名思义,它位于大脑前部,而顶叶则位于额叶正后方,靠近大脑后部。在我们的大脑处理感官信息和语言的过程中,顶叶扮演了很重要的角色。

这项研究表明,绿茶加强了这些大脑区域之间的相互影响,令我们回忆信息的能力得以加强。换言之,它为记忆提供了燃料。

有一件事必须要予以强调,那就是研究人员使用的是绿茶提取物,你必须得喝上好几杯普通绿茶才能够获得等量可能产生此作用的活性成分:表没食子儿茶素没食子酸酯(EGCG)。

这是一个小规模的研究,如果能够在更大规模的研究中取得相同结果会更好,但是即便如此,它们仍然耐人寻味。结合以往对于喝绿茶的认知益处的研究,还有更多证据表明,每天喝上几杯这种历史悠久的饮料,很有可能是你能为大脑所做的最健康的事。

该研究结果发表于《心理药物学》(Psychopharmacology)杂志。

原始出处:

André Schmidt, Felix Hammann, Bettina Wölnerhanssen, Anne Christin Meyer-Gerspach, Jürgen Drewe, Christoph Beglinger, Stefan Borgwardt. Green tea extract enhances parieto-frontal connectivity during working memory processing. Psychopharmacology, March 2014; DOI: 10.1007/s00213-014-3526-1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1788651, encodeId=65751e8865154, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sun Nov 09 00:10:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908163, encodeId=75e51908163c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 26 21:10:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691616, encodeId=df3f169161656, content=<a href='/topic/show?id=1a594e91229' target=_blank style='color:#2F92EE;'>#工作记忆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47912, encryptionId=1a594e91229, topicName=工作记忆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=582029274600, createdName=lvygwyt2791, createdTime=Wed Jul 30 08:10:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995893, encodeId=da6d1995893cf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 23 08:10:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787141, encodeId=b7411e8714121, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 03 10:10:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788152, encodeId=f3101e88152d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Aug 21 14:10:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402271, encodeId=b8cd14022e166, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Apr 19 09:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1788651, encodeId=65751e8865154, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sun Nov 09 00:10:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908163, encodeId=75e51908163c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 26 21:10:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691616, encodeId=df3f169161656, content=<a href='/topic/show?id=1a594e91229' target=_blank style='color:#2F92EE;'>#工作记忆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47912, encryptionId=1a594e91229, topicName=工作记忆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=582029274600, createdName=lvygwyt2791, createdTime=Wed Jul 30 08:10:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995893, encodeId=da6d1995893cf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 23 08:10:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787141, encodeId=b7411e8714121, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 03 10:10:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788152, encodeId=f3101e88152d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Aug 21 14:10:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402271, encodeId=b8cd14022e166, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Apr 19 09:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1788651, encodeId=65751e8865154, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sun Nov 09 00:10:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908163, encodeId=75e51908163c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 26 21:10:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691616, encodeId=df3f169161656, content=<a href='/topic/show?id=1a594e91229' target=_blank style='color:#2F92EE;'>#工作记忆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47912, encryptionId=1a594e91229, topicName=工作记忆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=582029274600, createdName=lvygwyt2791, createdTime=Wed Jul 30 08:10:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995893, encodeId=da6d1995893cf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 23 08:10:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787141, encodeId=b7411e8714121, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 03 10:10:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788152, encodeId=f3101e88152d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Aug 21 14:10:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402271, encodeId=b8cd14022e166, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Apr 19 09:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1788651, encodeId=65751e8865154, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sun Nov 09 00:10:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908163, encodeId=75e51908163c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 26 21:10:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691616, encodeId=df3f169161656, content=<a href='/topic/show?id=1a594e91229' target=_blank style='color:#2F92EE;'>#工作记忆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47912, encryptionId=1a594e91229, topicName=工作记忆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=582029274600, createdName=lvygwyt2791, createdTime=Wed Jul 30 08:10:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995893, encodeId=da6d1995893cf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 23 08:10:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787141, encodeId=b7411e8714121, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 03 10:10:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788152, encodeId=f3101e88152d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Aug 21 14:10:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402271, encodeId=b8cd14022e166, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Apr 19 09:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
    2015-01-23 yb6560
  5. [GetPortalCommentsPageByObjectIdResponse(id=1788651, encodeId=65751e8865154, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sun Nov 09 00:10:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908163, encodeId=75e51908163c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 26 21:10:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691616, encodeId=df3f169161656, content=<a href='/topic/show?id=1a594e91229' target=_blank style='color:#2F92EE;'>#工作记忆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47912, encryptionId=1a594e91229, topicName=工作记忆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=582029274600, createdName=lvygwyt2791, createdTime=Wed Jul 30 08:10:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995893, encodeId=da6d1995893cf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 23 08:10:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787141, encodeId=b7411e8714121, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 03 10:10:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788152, encodeId=f3101e88152d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Aug 21 14:10:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402271, encodeId=b8cd14022e166, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Apr 19 09:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
    2014-08-03 jj000001
  6. [GetPortalCommentsPageByObjectIdResponse(id=1788651, encodeId=65751e8865154, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sun Nov 09 00:10:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908163, encodeId=75e51908163c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 26 21:10:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691616, encodeId=df3f169161656, content=<a href='/topic/show?id=1a594e91229' target=_blank style='color:#2F92EE;'>#工作记忆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47912, encryptionId=1a594e91229, topicName=工作记忆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=582029274600, createdName=lvygwyt2791, createdTime=Wed Jul 30 08:10:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995893, encodeId=da6d1995893cf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 23 08:10:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787141, encodeId=b7411e8714121, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 03 10:10:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788152, encodeId=f3101e88152d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Aug 21 14:10:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402271, encodeId=b8cd14022e166, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Apr 19 09:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1788651, encodeId=65751e8865154, content=<a href='/topic/show?id=9641141647e' target=_blank style='color:#2F92EE;'>#pharmacology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14164, encryptionId=9641141647e, topicName=pharmacology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sun Nov 09 00:10:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908163, encodeId=75e51908163c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Jan 26 21:10:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691616, encodeId=df3f169161656, content=<a href='/topic/show?id=1a594e91229' target=_blank style='color:#2F92EE;'>#工作记忆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47912, encryptionId=1a594e91229, topicName=工作记忆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=582029274600, createdName=lvygwyt2791, createdTime=Wed Jul 30 08:10:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995893, encodeId=da6d1995893cf, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jan 23 08:10:00 CST 2015, time=2015-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787141, encodeId=b7411e8714121, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 03 10:10:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788152, encodeId=f3101e88152d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Aug 21 14:10:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402271, encodeId=b8cd14022e166, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Apr 19 09:10:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
    2014-04-19 hbwxf

相关资讯

Oral Oncol:饮绿茶可降低男性人群的口腔癌风险

研究要点1、绿茶摄入与男性口腔癌风险减少相关,而女性人群则未见此效应,吸烟越厉害的男性效果越好;无迹象表明红茶消费与口腔癌风险减少相关。2、日前,中国上海交通大学头颈癌研究中心的Zhi-Yuan Zhang博士等研究者发表于Oral Oncology的一项研究显示,绿茶消费或可减少男性人群特别是男性重度吸烟人群的口腔癌风险。这项基于住院人群的多中心病例对照研究旨在评估中国人群茶消费与口腔癌风险之间

Circ J:长期饮绿茶能降低冠心病风险

江苏省人民医院心内科教授王连生主任医师所带领的科研小组近日发布的临床研究表明:长期饮用绿茶可预防冠心病,不支持喝红茶可预防冠心病。相关研究成果先后刊发在日本循环杂志和美国临床营养杂志上。 据介绍,茶起源于中国,作为中国人饮食结构中不可或缺的元素,绿茶常被誉为“国饮”。但长期以来,关于绿茶效用的说法不一而足。 王连生教授自2008年起开始通过对照研究了520名首次

研究发现绿茶可提高认知能力,尤其是工作记忆

据美国每日科学网站4月7日报道,绿茶据说对健康大有裨益,现在,瑞士巴塞尔大学的研究人员称,他们首次有证据表明绿茶提取物能增强认知功能,尤其是工作记忆。《神经药理学杂志》刊登了他们的论文。 过去,绿茶的主要成分在癌症研究中得到全面探查。近日,科学家还一直在探究这种饮品对人脑的积极影响。有不同研究都将绿茶与认知表现的改善联系起来。然而,绿茶产生认知增强效应的神经机制始终是个谜。 在一项最新研究中,

饮用大量绿茶或可以抑制前列腺癌

  一项新的研究显示:饮用大量绿茶可以通过减少炎症,刺激细胞凋亡而抑制前列腺癌的发展。该研究由加利福利亚大学David Geffen医学院M.Henning博士发表在美国癌症研究学会(AACR)第11届癌症预防会议上。   M.Henning博士说,饮用绿茶的前列腺癌患者,与不饮用绿茶的患者比,前列腺组织的炎症较轻,这与癌生长和其他变化有关。   “我们可以表明绿茶多酚(抗氧化剂)到达前列腺组

Stroke:多饮绿茶和咖啡降低卒中风险

  日本一项大规模队列研究显示,多饮绿茶和咖啡与一般人群卒中风险呈负相关。论文2013年3月14日在线发表于《卒中》(Stroke)杂志。   研究纳入82369名受试者(年龄45~74岁,无心血管疾病及癌症),平均随访13年。结果为,与几乎不饮绿茶者相比,每日饮用绿茶分别为2~3杯或≥4杯者发生卒中的风险比(HR)为0.86和0.80;与几乎不饮咖啡者相比,饮咖啡3~6次/周、1次/日或≥2次

星岛日报:饮用绿茶或可预防糖尿病

据澳洲《星岛日报》报道,候伯特(Hobart)Menzies研究中心华裔博士生利用老鼠实验发现饮用绿茶的可预防糖尿病。 吴海伦(Helena Ng,音译)指出,被喂以不良饮食的实验老鼠通常会患上早期糖尿病,但同时饮用绿茶的却无发病。她表示,证实此大受欢迎的亚洲饮品于人类身上能同样起到预防疾病作用之前,她需要找出令人大量饮用的方法。 “大多数本地人不喜欢绿茶”,吴